Abstract
Despite its young life, genetic immunization (GI) has seen both fame and infamy. Initially under the limelight because of its appeal as a simple method of delivering vaccines, some experiments displayed disappointing immune potency and, consequently, excitement dimmed. Newer focus on the flexibility of GI, afforded by its foundation in molecular biology, has recently rekindled activity in the field. Approached as a recombinant DNA technology, deficiencies become addressable. Unlike any other subunit vaccine modality, such as protein or carbohydrate, DNA is chemically simple, stable, consistent, easily amplified and the base material of a vast array of bioconstruction and biocontrol techniques. GI provides scientists with a simple platform for merging other disciplines, such as molecular biology, biochemistry, genetics, chemistry, informatics and microbiology, into the development of superior vaccine products.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.